Ménétrier-like disease in a Pointer with concurrent granulomatous gastritis, helicobacteriosis and leishmaniosis: a case report by Lagerstedt, E. et al.
CASE REPORT Open Access
Ménétrier-like disease in a Pointer with
concurrent granulomatous gastritis,
helicobacteriosis and leishmaniosis: a case
report
E. Lagerstedt1*, T. Spillmann1, N. Airas2, L. Solano-Gallego3 and S. Kilpinen1
Abstract
Background: Ménétrier-like disease is a rare hypertrophic canine gastropathy, reported in only seven dogs. Clinical
signs are vomiting, anorexia and weight loss. Macroscopically, giant cerebriform gastric mucosal folds are typically
seen in the corpus and fundus of the stomach. Histopathologically, fundic mucous cell hyperplasia and loss of
parietal and chief cells are typical.
Case presentation: A nine-year-old spayed female Pointer had a history of intermittent vomiting, marked weight
loss and hypoalbuminaemia. A gastroduodenoscopy was performed three times within three months with
macroscopic changes remaining the same. The gastric mucosa of the corpus, fundus and proximal antrum was
markedly irregular, with cerebriform mucosal folds. In the first gastric biopsies, histopathology revealed a moderate
granulomatous gastritis, with a severe manifestation of Helicobacter-like organisms. Treatment for Helicobacter spp.
decreased the vomiting slightly. The dog was diagnosed with concurrent leishmaniosis; the conventional anti-
Leishmania treatment decreased the vomiting moderately, the hypoalbuminaemia resolved and the dog gained
weight back to a normal body condition. Granulomatous gastritis was not present in the gastric biopsies after these
treatments. The dog increased vomiting when palliative treatment (maropitant citrate, ondansetron and
esomeprazole) was discontinued, and thus, full-thickness biopsies of the stomach were taken and Ménétrier-like
disease was diagnosed. The affected area was too large to be surgically removed; thus, palliative treatment was
reinstated. The dog remained clinically well 39 months after the first clinical presentation.
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Conclusions: This is the first report of Ménétrier-like disease in a dog with a simultaneous manifestation of
granulomatous gastritis, helicobacteriosis and leishmaniosis. The clinical signs decreased after treatment of
helicobacteriosis and leishmaniosis, but vomiting remained probably as a sign of Ménétrier-like disease. Treatment
options for dogs are surgical removal of the abnormal area or palliative treatment. In humans, promising results for
a cure have been shown with cetuximab treatment, a human monoclonal antibody, but no canine antibody is
commercially available yet. The dog here was doing well 39 months after first presentation, which is the longest
reported survival time for Ménétrier-like disease with only palliative treatment in dogs. Full-thickness biopsies are
preferred in macroscopic hypertrophic lesions of the stomach for better assessment of Ménétrier-like disease.
Keywords: Ménétrier’s-like disease, Menetrier's disease, Giant hypertrophic gastritis, Helicobacter spp., Leishmania,
Foveolar hyperplasia
Background
Ménétrier’s disease (MD) is a rare hypertrophic gastro-
pathy in humans, characterized macroscopically by giant
cerebriform gastric mucosal folds in the corpus and fun-
dus of the stomach, sparing the antrum and pylorus [1,
2]. Histopathologically, hyperplasia of the mucous cells
within the neck and base areas of the fundic glands and
loss of parietal and chief cells are typical [1]. The criteria
for diagnosis of MD in dogs have not yet been estab-
lished in detail, which is why the term Ménétrier-like
disease (MLD), instead of MD, is preferred in dogs.
MLD has been reported earlier in only seven dogs repre-
senting five different breeds: a Boxer, an Old English
Sheepdog, a West Highland White Terrier, three Cairn
Terrier littermates and a Jack Russell Terrier [3–7]. In
all reported canine cases, hyperplasia of the mucous cells
in the corpus and fundus of the stomach was described,
and in four cases also the loss of parietal and chief cells
[6, 7]. The most common clinical signs and findings in
affected dogs include vomiting, anorexia, weight loss and
hypoalbuminaemia [3–7]. The aetiology underlying
MLD in dogs is unknown, but in humans and mice, one
factor in the pathogenesis of MD is suggested to be in-
creased signalling of epidermal growth factor receptors
(EGFR) [1]. In humans, MD usually shows chronic pro-
gressive features, but variants with acute onset and spon-
taneous remission have been reported, and have been
associated with Helicobacter pylori infection in adults
and cytomegalovirus (CMV) infection in children [2, 8].
This report describes for the first time the coexistence of
MLD with granulomatous gastritis, a severe manifest-
ation of Helicobacter-like organisms and leishmaniosis
in a Pointer.
Case presentation
A nine-year-old spayed female Pointer weighing 15 kg
was presented with a nine-month history of intermittent
vomiting and marked weight loss to the University of
Helsinki Veterinary Teaching Hospital, Finland. The dog
was born in Greece and had lived one year in Germany
before moving to Finland six years before presentation.
On physical examination, the dog´s body condition score
was 3/9 and it had mild periodontitis.
Complete blood count results were within reference
intervals. Serum biochemical abnormalities included
mild hypoproteinaemia, mild hypoalbuminaemia and
hypocobalaminaemia. C-reactive protein was mildly
elevated. Antibody titres against Leishmania infantum
antigens (immunofluorescence antibody test, Ludwig
Maximilian University of Munich) were markedly ele-
vated (Table 1). Serum gastrin concentration was 26 ng/l
(reference interval 10–40 ng/l, Michigan State Univer-
sity). To rule out hypoadrenocorticism, basal serum cor-
tisol concentration was measured and it was 34 nmol/l
(reference interval 10–100 nmol/l, IDEXX Laboratories)
[9]. Serum Dirofilaria immitis antigen and antibodies
against Borrelia burgdorferi, Anaplasma phagocytophi-
lum and Ehrlichia canis were negative (SNAP 4Dx,
IDEXX Laboratories).
Faecal examination for endoparasites by flotation, anti-
gen testing for Giardia duodenalis (FASTest Giardia)
and bacterial culture for Yersinia spp., Salmonella spp.,
Campylobacter spp., Clostridium difficile and Clostrid-
ium perfringens were negative. Urinalysis including urine
protein-creatinine ratio was unremarkable. Abdominal
ultrasonography revealed a partial mild gastric wall
thickening with slight loss of wall layering, mild thicken-
ing of the colonic wall with normal wall layering, en-
larged and slightly heterogenic medial iliac lymph nodes,
prominent mesenteric lymph nodes and hyperechoic
sports in both renal cortices.
To exclude food-responsive enteropathy, an elimin-
ation diet was started with a hydrolysed diet in addition
to palliative treatment comprising famotidine (Pepcid;
Janssen-Cilag, 0.7 mg/kg orally q12h), ondansetron
(Ondansetron Stada; Stada Arzneimittel, 0.3 mg/kg or-
ally q8h) and maropitant citrate (Cerenia; Zoetis,
3.2 mg/kg orally q24h). Cobalamin supplementation was
initiated (Betolvex; Ratiopharm, 0.06 mg/kg orally q24h).
Treatment for leishmaniosis was not started until
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gastroduodenoscopy was performed and gastric biopsies
examined.
Gastroduodenoscopy was performed one month after
the first presentation since the dog did not improve after
initiating treatment. The gastric mucosa of the corpus,
fundus and proximal antrum was macroscopically ir-
regular, showing cerebriform mucosal folds (Fig. 1a).
The distal antrum (Fig. 1b) and duodenum were macro-
scopically unremarkable. Histopathological examination
of the duodenum revealed a mild diffuse chronic lym-
phoplasmacytic enteritis with a mild multifocal neutro-
philic component. Gastric mucosal biopsies showed a
moderate multifocal chronic granulomatous gastritis
with fewer lymphocytes and plasma cells (Fig. 1c) and
occasional intralesional, round to ovoid, 3–6 µm in
diameter single-cell organisms, which were detected
both within the cytoplasm of macrophages and extracel-
lularly. In addition, severe manifestation of Helicobacter-
like organisms (HLOs) and multifocal mild cystic dilata-
tion of glands at the midlevel of the lamina propria were
observed. The organisms seen intralesionally stained
positively in both periodic acid Schiff’s (PAS) and
Grocott’s methenamine silver special stainings.
A PCR for fungi was performed on a fresh frozen gas-
tric mucosal biopsy sample (HUSLAB), and DNA from
Malassezia globosa was found [10]. Leishmania spp. was
examined by immunohistochemistry from a formalin
fixed gastric biopsy (Universitat Autònoma de Barce-
lona) and by real-time PCR from a fresh frozen gastric
biopsy (IDEXX Laboratories); both were negative [11].
Fluorescence in situ hybridization (FISH) from a forma-
lin fixed gastric biopsy detected eubacteria, but no sig-
nificant amounts of Escherichia coli, Salmonella spp.,
Helicobacter spp., Cryptococcus spp., Campylobacter
spp., Leptospira spp. or Streptococcus spp. (Langford
Vets Diagnostic Laboratories).
Based on these findings, the dog was treated for heli-
cobacteriosis with amoxicillin (Amovet vet; Orion,
25 mg/kg orally q12h), clarithromycin (Clarithromycin
Ratiopharm; Teva, 8 mg/kg orally q12h) and
Table 1 Summary of changes in clinical biochemistry parameters and results of additional diagnostic tests




25.7 NT 26.1 31.3 33.4 30.8 34.2 33.3 34.4 33.2
Total proteins (58–77 g/l) 53.0 NT 57.0 62.0 58.0 57.0 63.0 64.0 66.0 70.0
Cobalamin
(200–850 pg/ml)
163 NT 737 1180 NT 176 766 839 904 725
C-reactive protein
(< 10 mg/l)
26.2 45.4 < 10 NT NT NT NT NT NT NT
Leishmania infantum antibodies (< 1:32) 1:512 NT NT NT NT 1:256 NT NT 1:64 1:64
Values beyond the reference interval are bolded
FP First presentation, MAFP Months after the first presentation, NT Not tested
Fig. 1 First gastroduodenoscopy. a Endoscopic view of gastric corpus and proximal antrum showing cerebriform thickened gastric mucosal folds.
b Endoscopic view of distal antrum and pylorus was macroscopically unremarkable. c Histopathology of the gastric mucosal biopsy showing
multifocal moderately increased number of macrophages (arrow), lymphocytes and plasma cells. Haematoxylin and eosin staining 20X. Insert:
Numerous spiral-shaped Helicobacter-like organisms (arrow) are present in gastric mucosa. Warthin-Starry silver staining, bar 5 µm
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metronidazole (Metronidazol Ratiopharm; Ratiopharm,
8 mg/kg orally q12h) for two weeks. The palliative treat-
ment continued with ondansetron and maropitant cit-
rate, in addition to esomeprazole (Nexium; AstraZeneca,
1 mg/kg orally q24h). Oral supplementation of cobala-
min was also continued.
One month later, the dog still vomited every other
day. A second gastroduodenoscopy was performed. The
gastric mucosal changes had the same magnitude and
cerebriform appearance as in the first gastroduodeno-
scopy (Fig. 2a). Histopathological examination revealed a
severe diffuse chronic lymphoplasmacytic gastritis with
fewer macrophages. Some single-cell organisms were
still present, but HLOs were no longer detected (Fig. 2b).
The palliative treatment was continued. Based on the
high antibodies against L. infantum antigens and persist-
ent clinical signs, treatment for leishmaniosis was started
according to LeishVet guidelines [12] with miltefosine
(Milteforan; Virbac, 2 mg/kg orally q24h for 4 weeks)
and allopurinol (Zyloric; Aspen, 10 mg/kg orally q12h).
One month later, the vomiting had stopped and the
dog had gained weight. Serum total protein and albumin
concentrations increased to the reference intervals, after
which the oral cobalamin supplementation was discon-
tinued. A third gastroduodenoscopy was performed. The
macroscopically changed mucosal area was the same size
and had the same appearance as during the first two en-
doscopies, but the mucosa was somewhat firmer (Fig. 3a).
Histopathological examination now revealed a moderate
diffuse chronic eosinophilic gastritis (Fig. 3b). Mild
granulomatous inflammation was noted only focally in
the corpus area. Single-cell organisms seen previously
were no longer detected, but a small number of HLOs
was seen. The palliative treatment and allopurinol were
continued.
Seven months after the first presentation, the dog
showed signs of heat for the first time after being spayed
seven years earlier in Greece and was diagnosed ultraso-
nographically with an ovarian remnant on the left side.
A laparotomy was performed and the ovarian remnant
was removed and two full-thickness biopsies were taken
from the gastric fundus and antrum. The aerobic and
anaerobic bacterial culture of the gastric biopsies was
negative. Histological examination of the fundic biopsy
showed hyperplasia of the mucous cells within the neck
and base areas of the fundic glands, multifocal cystic
enlargement of mucinous glandular structures at the
border between the lamina propria and lamina muscu-
laris mucosae and loss of parietal and chief cells (Fig. 4).
Occasional glandular structures were growing between
the muscular bundles on the lamina muscularis mu-
cosae. The fundic glandular changes were consistent
with the histopathological findings described in MD. A
mild multifocal granulomatous inflammation in the sub-
mucosa remained. There were no specific histopatho-
logical changes in the antral biopsy.
The dog had gained weight, achieving a normal body
condition score (5/9), and with palliative treatment and
Fig. 2 Second gastroduodenoscopy. a Endoscopic view of the gastric corpus and proximal antrum showing the same giant cerebriform gastric
mucosal folds as in the first endoscopy. b Histopathology of the gastric mucosal biopsy after treatment for Helicobacter-like organisms revealing a
severe chronic diffuse lymphoplasmacytic gastritis (lymphocytes short arrow, plasma cells long arrow) with a decreased number of macrophages
relative to the first gastric biopsies. Haematoxylin and eosin staining 20X. Insert: No Helicobacter-like organisms were detected. Warthin-Starry
silver staining, bar 5 µm
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allopurinol it had only vomited approximately twice a
month. The palliative medications continued, but at a
lower dose, with esomeprazole 0.7 mg/kg orally q24h,
maropitant citrate 0.8 mg/kg orally q24h and ondanse-
tron 0.3 mg/kg orally q24h. If any of the palliative medi-
cations were stopped or titrated down, the dog started
vomiting again daily.
Ten months after the first examination, the dog devel-
oped hypocobalaminaemia again (Table 1), so cobalamin
was started orally at 0.03 mg/kg q24h. Oral cobalamin
supplementation was successful again (Table 1). Serum
albumin concentration remained within the reference
interval. Thirty-nine months after the first presentation,
the dog was still on allopurinol, ondansetron and maro-
pitant citrate and was vomiting approximately twice a
month.
Discussion and conclusions
This case report describes the coexistence of two rare
gastropathies in the dog, namely MLD and
granulomatous gastritis, with simultaneous helicobacter-
iosis and leishmaniosis. The pathogenesis of MLD in
dogs is unknown, but in MD in humans and mice, one
factor is suggested to be increased signalling of EGFR
[1]. Especially in children, MD is strongly associated
with CMV infection, and CMV has been shown to acti-
vate EGFR signalling [2]. In CMV-associated cases, there
is a spontaneous remission of MD [2]. Especially in
adults, some MD cases have been associated with H. pyl-
ori infection and the eradication of H. pylori has resolved
the endoscopic and histopathological findings [8]. In this
dog, a severe manifestation of HLOs was present in the
first mucosal biopsies of the stomach, which has not pre-
viously been reported in MLD cases in dogs [3–7].
The dog showed chronic upper gastrointestinal signs,
such as weight loss, anorexia and vomiting in connection
with hypoalbuminaemia, which are typical clinical signs
for MLD in dogs and MD in humans [1, 3–5, 7]. In this
case, vomiting slightly decreased when palliative treat-
ment was initiated and later slightly more with
Fig. 3 Third gastroduodenoscopy. a Endoscopic view of the gastric corpus and proximal antrum showing the same giant cerebriform gastric
mucosal folds as in the previous endoscopies. b Histopathology of the gastric mucosal biopsy revealed fundic glands surrounded by eosinophilic
granulocytes (arrow), lymphocytes and plasma cells. Haematoxylin and eosin staining 40X.
Fig. 4 Histopathology of the full-thickness biopsies of the fundus showing histopathological features of MD. a Cystic enlargement of mucinous
glandular structures (arrow). Haematoxylin and eosin staining 10X. b Hyperplasia of the mucous cells (arrow head) and loss of parietal cells (short
arrow) and chief cells (long arrow). Haematoxylin and eosin staining 40X.
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treatment for Helicobacter spp., but it did not cease. The
Helicobacter spp. treatment also did not result in reso-
lution of MLD. This could be explained with the chronic
features of the dogs’ disease. H. pylori –associated MD
in humans going into remission, typically has an acute
onset of symptoms [2]. After treatment for leishmanio-
sis, the vomiting ceased, the dog gained weight and the
hypoalbuminaemia resolved. It seems likely that part of
the clinical signs were caused by leishmaniosis. Six
months after the miltefosine treatment, the antibody ti-
tres against L. infantum had halved, indicating that the
leishmaniosis was in remission. The dog always started
vomiting if any of the palliative treatment medications:
maropitant citrate, ondansetron or esomeprazole, were
stopped or titrated down. At this point, the vomiting
was probably a sign of MLD.
In humans, treatments other than H. pylori eradica-
tion for MD have also been tried, such as antibiotics,
steroids, acid suppressants, anticholinergic agents and
octreotide therapy, but the findings have been incon-
sistent [2, 13]. In humans, promising results have
been shown with cetuximab, a human monoclonal
antibody that blocks EGFR signalling [1]. A “cani-
nized” anti-EGFR antibody has been investigated only
in vitro in canine cancer, however, no canine anti-
EGFR antibody is commercially available. Human
anti-EGFR antibodies could cause adverse reactions in
dogs such as anaphylaxis [14]. Partial or total gastrec-
tomy has been done in cases with severe symptoms,
and it has been reported to be a successful treatment
also in two canine cases [2, 5, 7, 13]. In this case, the
affected area was too large to be removed surgically
without affecting the function of the stomach; pallia-
tive treatment was given since the dog responded to
it. Thirty-nine months after first presentation, the dog
was clinically well, vomiting approximately twice a
month, despite the low daily doses of the palliative
treatments. Previously, the longest reported survival
time in a dog not treated surgically was 27 months
[6]. That dog had a subclinical disease for two years,
but was given a gastric protectant, a proton pump in-
hibitor and a non-steroidal anti-inflammatory drug for
an unknown period [6].
The dog here was hypocobalaminaemic and was sup-
plemented orally with cobalamin [15]. The supplementa-
tion led to hypercobalaminaemia and was discontinued,
after which the dog developed hypocobalaminaemia
again. In dogs, aetiologies for hypocobalaminaemia are
exocrine pancreatic insufficiency, chronic inflammatory
enteropathies and alimentary lymphoma among others
[16]. This dog showed no evidence of these diseases. In
the stomach, free cobalamin is bound to haptocorrin,
which in dogs is mostly produced by parietal cells in the
gastric mucosa [17]. Haptocorrin is digested by
pancreatic proteases in the duodenum and then free co-
balamin is bound to intrinsic factor [16]. Intrinsic factor
is mainly produced in dogs by the exocrine pancreas,
but also in the stomach in parietal cells [16, 17]. Parietal
cells, which produce both haptocorrin and intrinsic fac-
tor, are typically lost in MD [1, 16, 17], which could be
one possible factor contributing to the hypocobalami-
naemia in this dog.
The serum gastrin concentration was measured to
rule out gastrinoma as a differential diagnose for the
hypertrophic changes in the stomach. The typical
changes of MLD were not evident in the endoscopic
gastric mucosal biopsies, but the diagnosis was
achieved from the full-thickness biopsies. In humans,
the diagnosis for MD is obtained from endoscopic bi-
opsies, but large snare biopsies are recommended in
macroscopically hypertrophic lesions, instead of stand-
ard forceps biopsies [2]. In the previous canine case
reports, the diagnosis was made from full-thickness
biopsies in all cases [3–7]. In one case, the first biop-
sies were taken by gastroscopy and they had con-
tained only the superficial part of the mucosa from
which the diagnosis of MLD could not be made [3].
In the case presented here, it is uncertain why the
characteristic changes of MLD were not seen in the
first three endoscopic mucosal biopsies because all
samples had contained the lamina propria of the gas-
tric mucosa and the macroscopic appearance of the
gastric lesion at the endoscopies and the laparotomy
had remained the same. Based on this, full-thickness
biopsies should probably be the preferred method in
dogs with suspected MLD. Full-thickness biopsies are
also more accurate for the evaluation of possible neo-
plastic changes. People with MD have a higher risk of
developing gastric neoplasia [1]. Four cases of MLD
in dogs have been reported to progress to gastric car-
cinoma [5, 6]. In three littermates, gastric adenocar-
cinoma was diagnosed [6]. In two of the dogs, the
diagnosis was set at the same time as the diagnosis of
MLD [6]. In the third dog, the diagnosis was made
27 months after diagnosis of MLD [6]. In one dog, a
poorly differentiated superficial gastric carcinoma was
diagnosed five years after a partial gastrectomy was
done and MLD was diagnosed [5].
Granulomatous gastritis in dogs is far less common
than lymphoplasmacytic or eosinophilic gastritis and has
been described in rare cases of infections caused by
fungi, parasites or bacteria [18]. The cause for the granu-
lomatous gastritis in this dog was extensively examined,
yet remained unknown. Granulomatous inflammation in
the gastrointestinal tract of dogs in endemic areas of
leishmaniosis has been reported in L. infantum infection
[19]. However, L. infantum was not detected in the gas-
tric biopsies by PCR or immunohistochemistry. The
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aerobic and anaerobic bacterial culture of the biopsy was
negative. The PCR examination for fungi revealed a
small amount of DNA from M. globosa. The PAS-
positive intralesional structures in the stomach were
morphologically compatible with single-cell yeast.
Malassezia spp. was not thought to be the cause for the
granulomatous gastritis. The PAS-positive structures
also disappeared from the biopsies without a treatment
for Malassezia spp. FISH detected eubacteria within the
gastric tissue samples, but not significant numbers of E.
coli, Salmonella spp., Helicobacter spp., Cryptococcus
spp., Campylobacter spp., Leptospira spp. or Streptococ-
cus spp. It is unclear why the severe manifestation of
HLO was not detected by FISH since in previous studies
Helicobacter spp. have been detected by FISH with high
sensitivity [20, 21]. In one study, Helicobacter spp. was
detected by FISH in all gastric biopsies, but in a few bi-
opsies from the small and large intestine they were not
detected by FISH, even though Helicobacter spp. PCR
had been positive [20]. This was thought to be associated
with either a difficulty of the probes in penetrating the
crypts or too few bacteria in the sample [20]. This could
also be the case in our biopsies.
The role of Helicobacter spp. in the granulomatous
gastritis of this dog is unknown. Typically, Helicobacter
spp. infection in dogs manifests as mild lymphoplasma-
cytic gastritis, but can also be asymptomatic [22, 23]. In
some human cases, it has been suggested that there
might be an association between H. pylori infection and
granulomatous gastritis [24, 25]. In this case, the severity
of the granulomatous gastritis markedly decreased after
the treatment for Helicobacter spp, which supports a
possible connection between the two conditions. How-
ever, we cannot exclude a response to the simultaneous
treatment of leishmaniosis. Two months after the treat-
ment, Helicobacter spp. were detected again in the gas-
tric biopsies. Recurrence of gastric Helicobacter spp.
after eradication is a common finding in dogs [26].
In conclusion, the dog was diagnosed with MLD, granu-
lomatous gastritis, severe helicobacteriosis and leishma-
niosis. The clinical signs decreased after treatment of
helicobacteriosis and leishmaniosis, but mild chronic
vomiting remained probably as a sign of MLD. The dog
was doing well 39 months after the first presentation,
which is the longest reported survival time for canine
MLD with palliative treatment. Full-thickness biopsies are
valuable in macroscopic hypertrophic lesions of the stom-
ach for better assessment of the disease.
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